Skip to main content
    A

    Actinium Pharmaceuticals Inc (ATNM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.33
    -0.16 (-10.74%)

    Market Cap: $46.85M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Actinium Pharmaceuticals Inc (ATNM) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Actinium Pharmaceuticals (ATNM) has a market cap of $46.85M and an enterprise value of $18.17M. Revenue grew 3788.89% over the last 12 months from the 12 months before. It holds $28.68M more cash than debt, 61.21% of its market cap.

    Total Valuation

    Enterprise value is 61.21% below the market cap, as cash exceeds debt.

    Market Cap$46.85M
    Enterprise Value$18.17M
    Latest price (Nov 17, 2026)$1.33

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.13% in the quarter ended Sep 30, 2026 and grew 0.59% a year over 2 years.

    Shares Outstanding31.44M
    Shares Change (YoY)+0.79%
    Shares Change (QoQ)+0.13%
    Share Count Growth (2Y CAGR)+0.59%

    Valuation Ratios

    Sales and book value multiples are 1.2x and 1.7x.

    P/E Ratio4.0x
    P/S Ratio1.2x
    Forward P/S1.3x
    P/B Ratio1.7x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 1.4x EBITDA.

    EV / Earnings1.7x
    EV / Sales0.5x
    EV / EBITDA1.4x

    Price Statistics

    The stock is up 4.72% over 52 weeks and trades 2.31% above its 50-day average.

    Beta (1Y)0.83
    52-Week Change+4.72%
    1-Month Change+0.76%
    3-Month Change+17.70%
    6-Month Change+15.65%
    5-Year Change-81.15%
    10-Year Change-94.81%
    Total Return (1Y)+4.72%
    Total Return (3Y CAGR)-33.33%
    Total Return (5Y CAGR)-29.71%
    Return vs SPY (1Y)-18.55%
    Max Drawdown (1Y)-55.70%
    Max Drawdown (3Y)-92.43%
    Sharpe Ratio (1Y)-0.10
    Correlation with SPY (1Y)0.16
    50-Day Average$1.30
    200-Day Average$1.13
    52-Week Range$0.73 to $1.72
    RSI (14 Days)46.1
    Average Volume (20 Days)245.76K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.00x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.00x
    Quick Ratio4.00x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 43.10% and return on assets is 32.64% over the last 12 months.

    Return on Equity (ROE)43.10%
    Return on Assets (ROA)32.64%
    ROA (5Y Average)-46.97%
    Asset Turnover0.79x

    Taxes

    Income tax took 0.00% of pretax income over the last 12 months.

    Income Tax (TTM)$0
    Effective Tax Rate0.00%

    Scores

    ATNM has an Altman Z-Score of -10.95, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score-10.95
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $35.00M over the last 12 months.

    Revenue$35.00M
    Revenue Growth (YoY)+3788.89%
    Gross Profit$35.62M
    Operating Income$9.13M
    Pretax Income$10.60M
    Net Income$10.60M
    Reported EPS (TTM)$0.33

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 75.73% of the $32.47M in total assets.

    Cash and Equivalents$28.68M
    Total Debt$0
    Net Cash$28.68M
    Net Cash Per Share$0.91
    Working Capital$22.12M
    Shareholder Equity$24.59M
    Book Value Per Share$0.78
    Total Assets$32.47M
    Total Liabilities$7.88M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.35M of capital spending, operating cash flow left -$24.71M of free cash flow.

    Operating Cash Flow-$23.36M
    Capital Expenditures$1.35M
    Free Cash Flow-$24.71M
    FCF Per Share-$0.79
    Depreciation and Amortization$1.31M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 26.07%.

    Gross Margin101.76%
    Operating Margin26.07%
    Pretax Margin30.27%
    Net Margin30.27%
    FCF Margin-70.61%

    Growth

    Revenue fell 55.63% a year over 3 years.

    Revenue Growth (3Y CAGR)-55.63%
    Book Value Per Share Growth (2Y CAGR)-56.32%
    Tangible Book Per Share Growth (2Y CAGR)-56.32%

    Revenue and profit by year

    Dividends and Yields

    ATNM does not pay a dividend. Its free cash flow yield is -59.10%.

    Earnings Yield25.00%
    FCF Yield-59.10%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-30 reverse split on Aug 11, 2020.

    Last Split DateAug 11, 2020
    Split TypeReverse split
    Split Ratio1:30

    Peer Position

    Against 4 similar companies, ATNM has the lowest P/S.

    P/S Ratio1.2x vs 124.6x median
    Revenue Growth (Trailing 4 Quarters, YoY)+3788.89% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 38788.89% a year over the next fiscal year.

    Revenue Growth Forecast (1Y CAGR)+38788.89%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ATNM

    What is ATNM's market cap?

    Actinium Pharmaceuticals has a market cap of $46.85M. Its enterprise value, which adds debt and subtracts cash, is $18.17M.

    What is ATNM's P/E ratio?

    Actinium Pharmaceuticals has a trailing P/E ratio of 4.0x.

    How many shares of ATNM are outstanding?

    Actinium Pharmaceuticals has 31.44M shares outstanding. The count is up 0.79% from a year earlier.

    Does ATNM pay a dividend?

    No. Actinium Pharmaceuticals does not pay a dividend.

    How much debt does ATNM have?

    Actinium Pharmaceuticals has $0 of total debt and $28.68M of cash and equivalents, a net cash position of $28.68M.